RxDoctor Payments Data

Bridgeida Elhazin

Nurse Practitioner · Loma Linda, CANPI 1144252370

Payments from drug & device makers

$7,325in general payments, 2019–2025

Across 64 payments — averaging $114.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • AbbVie$863
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$89
  • Ipsen Biopharmaceuticals, Inc$61
  • Boston Scientific$52
  • Mallinckrodt Hospital Products Inc.$49
  • plus $118 from 4 others

What the payments were for

  • Consulting fees$1,57021%
  • Speaking & faculty fees$2,80538%
  • Travel & lodging$1,34518%
  • Food & beverage$1,60522%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,325 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$48,761
Medicare patients
253
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin111$369,417
Tacrolimus366$33,835
Everolimus12$33,368
VeltassaPatiromer Calcium Sorbitex31$30,011
Ursodiol174$25,530
LokelmaSodium Zirconium Cyclosilicate11$17,689
Entecavir66$17,636
Tenofovir Disoproxil Fumarate16$6,468
Mycophenolate Mofetil61$5,417
Lactulose110$5,360
Azathioprine33$2,089
Mycophenolic AcidMycophenolate Sodium16$1,883
Spironolactone126$1,625
Furosemide135$808
ConstuloseLactulose22$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$89$369,417111 claims
AstraZenecaLokelma$38$17,68911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →